KR960705848A - 자가면역 질병의 면역 치료에 사용하기 위해 자가항원으로부터 유도된 신규의 펩티드(novel peptides derived from autoantigen for use in immunotheraphy of autoimmune disease) - Google Patents

자가면역 질병의 면역 치료에 사용하기 위해 자가항원으로부터 유도된 신규의 펩티드(novel peptides derived from autoantigen for use in immunotheraphy of autoimmune disease)

Info

Publication number
KR960705848A
KR960705848A KR1019960702711A KR19960702711A KR960705848A KR 960705848 A KR960705848 A KR 960705848A KR 1019960702711 A KR1019960702711 A KR 1019960702711A KR 19960702711 A KR19960702711 A KR 19960702711A KR 960705848 A KR960705848 A KR 960705848A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
peptides
peptide according
peptide
Prior art date
Application number
KR1019960702711A
Other languages
English (en)
Other versions
KR100485979B1 (ko
Inventor
마리아 헬레나 부츠 안나
프란시스쿠스 마리아 베르하이덴 기스베르투스
Original Assignee
에프.지.엠. 헤르만스.이. 에이취. 리링크
악조 노벨 엔. 브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.지.엠. 헤르만스.이. 에이취. 리링크, 악조 노벨 엔. 브이 filed Critical 에프.지.엠. 헤르만스.이. 에이취. 리링크
Publication of KR960705848A publication Critical patent/KR960705848A/ko
Application granted granted Critical
Publication of KR100485979B1 publication Critical patent/KR100485979B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 아미노산 서열 FGRSFTLAS(서열 번호 1), FTILASSETG(서열 번호 2), YDDQQESSVKS(서열 번호 3) 및 FSKIASNTQ(서열 번호 4) 중에서 하나 이상의 서열을 포함하는, 자가항원 HC gp-39로부터 유도된 신규한 펩티드에 관한 것이다. 상기 펩티드는 관절 연골내의 자가항원 Hc gp-39상에 존재하는 MHC 클래스 Ⅱ 제한된 T-세포 에피토프와 유사하다. HC gp-39 및 상기 펩티드는 면역 시스템의 내성을 유도하는, 자가면역 질병에서 관절 연골 파괴의 항원-특이성 치료에 사용할 수 있다. 또한, 자가항원 HC gp-39 및 상기 펩티드는 인간을 제외한 포유동물, 바람직하게는 생쥐에서 관절염을 유도하는데 사용할 수 있다. 또한, 본 발명은 상기 자가항원 및/또는 상기 펩티드를 포함하는 약학 조성물, 테스트 샘플 내에서 자가반응성 T-세포를 검출하는 진단 방법 및 상기 방법에 사용되는 테스트 키트에 관한 것이다.

Description

자가면역 질병의 면역 치료에 사용하기 위해 자가항원으로부터 유도된 신규의 펩티드(NOVEL PEPTIDES DERIVED FROM AUTOATIGEN FOR USE IN IMMUNOTHERAPHY OF AUTOIMMUNE DISEASE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 HC gp-39 내성화한 Balb/c 생쥐 및 비-내성화한 Balb/c 생쥐에서 관절염의 개시 및 진행을 나타내는 도면이다.

Claims (16)

  1. 아미노산 서열 FGRSFTLAS(서열 번호 1), FTILASSETG(서열 번호 2), YDDQQES
    SVKS(서열 번호 3) 및 FSKIASNTQ(서열 번호 4) 중에서 하나 이상의 서열을 포함하는, 자가항원 HC gp-39의 부분서열을 포함하는 펩티드.
  2. 제1항에 있어서, 아미노산 서열 PTFGRSFTLASSE(서열 번호 5), RSFTLASSETGVG
    (서열 번호 6), VGYDDQESVKSKV(서열 번호 7), SQRFSKIASNTQSR(서열 번호 8)중 하나 이상의 서열을 포함하는 펩티드.
  3. 제1항 또는 제2항에 있어서, 아미노산 서열 PTFGRSFTLASSE(서열 번호 5)을 보유하는 펩티드.
  4. 제1항 또는 제2항에 있어서, 아미노산 서열 RSFTLASSETGVG(서열 번호 6)을 보유하는 펩티드.
  5. 제1항 또는 제2항에 있어서, 아미노산 서열 VGYDDQESVKSKV(서열 번호 7)을 보유하는 펩티드.
  6. 제1항 또는 제2항에 있어서, 아미노산 서열 SQRFSKIASNTQSR(서열 번호 8)을 보유하는 펩티드.
  7. 치료 물질로 사용하기 위한 HC gp-39 단백질 또는 제1항 내지 제6항 중 어느 한 항에 따른 펩티드.
  8. HC gp-39 단백질 또는 제1항 내지 제6항 중 어느 한 항에 따른 펩티드 및 약학적으로 허용가능한 담체를 포함하는 약학 조성물.
  9. T-세포 중재된 연골 파괴로 고생하는 환자에서 HC gp-39 자가항원에 대한 특이성 T-세포 내성을 유도하기 위한 약제를 제조하기 위해 HC gp-39 단백질 또는 제1항 내지 제6항 중 어느 한 항에 따른 펩티드중 하나 이상의 펩티드를 사용하는 방법.
  10. 관절염, 구체적으로 류마티스성 관절염으로 고생하는 환자에서 HC gp-39 자가항원에 대한 특이성 T-세포 내성을 유도하기 위한 약제를 제조하기 위해 HC gp-39 단백질 또는 제1항 내지 제6항 중 어느 한 항에 따른 펩티드중 하나 이상의 펩티드를 사용하는 방법.
  11. 인간을 제외한 포유동물, 바람직하게는 생쥐에서 임상적 관절염을 유도하는방법에 사용하기 위한 HC gp-39 단백질 또는 제1항 내지 제6항 중 어느 한 항에 따른 펩티드중 하나 이상의 펩티드.
  12. 진단 물질로 사용하기 위한 제1항 내지 제6항 중 어느 한 항에 따른 펩티드.
  13. 제1항 내지 제6항 중 어느 한 항에 따른 펩티드중 하나 이상의 펩티드 및 검출 시약을 포함하는 진단 조성물.
  14. (a) 개체의 혈액 샘플로부터 말초 혈액 단핵 세포(PBMC)를 분리하는 단계; (b) 적합한 조건하에서 상기 PBMC를 배양하는 단계; (c) HC gp-39, 이의 단편 및/또는 제1항 내지 제6항 중 어느 한 항에 따른 펩티드중 하나 이상의 펩티드 존재하에서 상기 PBMC 배양액을 항온처리하는 단계; 및 (d) 개체에서 활성화된 자가반응성 T-세포의 존재를 의미하는 T-세포의 반응을 검출하는 단계를 포함하는, 활성화된 자가반응성 T-세포 검출을 위한 진단 방법.
  15. HC gp-39 단백질 또는 제1항 내지 제6항 중 어느 한 항에 따른 펩티드중 하나 이상의 펩티드를 포함하는, 활성화된 자가반응성 T-세포 검출용 테스트 키트.
  16. 9 내지 55개의 아미노산 잔기로 이루어진 아미노산을 보유하는 제1항 내지 제15항 중 어느 한 항에 따른 펩티드.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702711A 1994-10-27 1995-10-25 자가면역질병의 면역치료에 사용하기 위한 자가항원으로부터 유도된 신규의 펩티드 KR100485979B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP94203128 1994-10-27
EP94203128.7 1994-10-27
EP95200886 1995-04-07
EP95200886.0 1995-04-07
PCT/EP1995/004201 WO1996013517A1 (en) 1994-10-27 1995-10-25 Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases

Publications (2)

Publication Number Publication Date
KR960705848A true KR960705848A (ko) 1996-11-08
KR100485979B1 KR100485979B1 (ko) 2006-01-27

Family

ID=26136688

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702711A KR100485979B1 (ko) 1994-10-27 1995-10-25 자가면역질병의 면역치료에 사용하기 위한 자가항원으로부터 유도된 신규의 펩티드

Country Status (24)

Country Link
US (1) US5736507A (ko)
EP (1) EP0733065B1 (ko)
JP (1) JP3755894B2 (ko)
KR (1) KR100485979B1 (ko)
CN (1) CN1161379C (ko)
AT (1) ATE177756T1 (ko)
AU (1) AU696827B2 (ko)
BR (1) BR9506377A (ko)
CA (1) CA2173874A1 (ko)
DE (1) DE69508380T2 (ko)
DK (1) DK0733065T3 (ko)
ES (1) ES2130672T3 (ko)
FI (1) FI118472B (ko)
GR (1) GR3030296T3 (ko)
HK (1) HK1002012A1 (ko)
HU (1) HU218027B (ko)
IL (1) IL115744A (ko)
MX (1) MX9602495A (ko)
NO (1) NO316703B1 (ko)
NZ (1) NZ295659A (ko)
PL (1) PL183761B1 (ko)
RU (1) RU2178797C2 (ko)
TR (1) TR199501326A2 (ko)
WO (1) WO1996013517A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US6881824B1 (en) 1996-04-24 2005-04-19 Akzo Nobel N.V. Peptides suitable for use in antigen specific immunosuppressive therapy
IL120561A0 (en) 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
EP1100526A2 (en) * 1998-07-23 2001-05-23 Akzo Nobel N.V. USE OF HC gp-39 IN IMMUNE DISEASES
KR20010071020A (ko) * 1998-07-23 2001-07-28 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 자가 면역 질환의 면역 요법에서 사용하기 위한 신규한펩티드
AU780238B2 (en) * 1999-10-18 2005-03-10 Akzo Nobel N.V. Modified peptides and peptidomimetics for use in immunotherapy
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
HUP0400659A3 (en) * 2001-07-24 2005-06-28 Zhu Zhou Woodbridge Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
WO2005081980A2 (en) * 2004-02-25 2005-09-09 Medimmune, Inc. Methods and compositions relating to chitinases and chitinase-like molecules and modulation of osteoclasts
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
RU2302872C9 (ru) * 2006-06-22 2008-12-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее функции хрящевой ткани, и способ его получения
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CA2696563A1 (en) 2007-08-15 2009-02-19 Circassia Limited Peptides for vaccine
EP2153841B2 (en) 2008-08-15 2015-11-11 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
EP2331124A1 (en) * 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
GB2469894B (en) 2009-02-05 2011-09-07 Circassia Ltd Peptides for use in treating allergy to grass pollen
CA2778669C (en) * 2009-10-27 2019-04-16 Erytech Pharma Composition to induce specific immune tolerance
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6323898A (ja) * 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices

Also Published As

Publication number Publication date
HK1002012A1 (en) 1998-07-24
TR199501326A2 (tr) 1996-06-21
DE69508380T2 (de) 1999-09-09
KR100485979B1 (ko) 2006-01-27
NZ295659A (en) 1998-02-26
US5736507A (en) 1998-04-07
WO1996013517A1 (en) 1996-05-09
DK0733065T3 (da) 1999-10-11
RU2178797C2 (ru) 2002-01-27
IL115744A (en) 2000-07-16
JPH09507861A (ja) 1997-08-12
FI962619A (fi) 1996-06-25
PL183761B1 (pl) 2002-07-31
HUT74847A (en) 1997-02-28
IL115744A0 (en) 1996-01-19
ES2130672T3 (es) 1999-07-01
GR3030296T3 (en) 1999-09-30
MX9602495A (es) 1997-05-31
AU3925295A (en) 1996-05-23
FI118472B (fi) 2007-11-30
BR9506377A (pt) 1997-09-16
HU218027B (hu) 2000-05-28
PL315198A1 (en) 1996-10-14
DE69508380D1 (de) 1999-04-22
AU696827B2 (en) 1998-09-17
HU9601401D0 (en) 1996-07-29
CN1161379C (zh) 2004-08-11
NO962695L (no) 1996-06-26
CA2173874A1 (en) 1996-05-09
CN1168677A (zh) 1997-12-24
NO316703B1 (no) 2004-04-13
FI962619A0 (fi) 1996-06-25
NO962695D0 (no) 1996-06-26
EP0733065B1 (en) 1999-03-17
ATE177756T1 (de) 1999-04-15
EP0733065A1 (en) 1996-09-25
JP3755894B2 (ja) 2006-03-15

Similar Documents

Publication Publication Date Title
KR960705848A (ko) 자가면역 질병의 면역 치료에 사용하기 위해 자가항원으로부터 유도된 신규의 펩티드(novel peptides derived from autoantigen for use in immunotheraphy of autoimmune disease)
Kuwana et al. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.
Taneja et al. HLA class II transgenic mice as models of human diseases
Boyton et al. Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice.
BG61164B1 (bg) Ваксиниране и методи за въздействие на заболявания, резултат от патогенни отговори на т-клетъчно специфични популации
RU96115937A (ru) Новые пептиды, являющиеся производными аутоантигена, предназначенные для использования в иммунотерапии аутоиммунных заболеваний
HUP9903378A2 (hu) Az autoimmun betegségek immunterápiájában felhasználható autoantigének és ezekkel szerkezetileg rokon fehérjék
Yu et al. Molecular mimicry in HLA-B27-related arthritis
Jahn-Schmid et al. Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1∗ 01
Bohle et al. Characterization of T cell responses to Hev b 3, an allergen associated with latex allergy in spina bifida patients
Monneaux et al. Key sequences involved in the spreading of the systemic autoimmune response to spliceosomal proteins
Ostenstad et al. Evidence for monoclonal expansion of synovial T cells bearing V alpha 2.1/V beta 5.5 gene segments and recognizing a synthetic peptide that shares homology with a number of putative autoantigens.
Targoff Immune mechanisms in myositis
Okamoto et al. Proliferative responses of peripheral blood mononuclear cells from patients with Graves' disease to synthetic peptides epitopes of human thyrotropin receptor
Davey et al. TCRB clonotypes are present in CD4 T cell populations prepared directly from rheumatoid synovium
Roudier et al. Tolerance to a self peptide from the third hypervariable region of the E chain. Implications for molecular mimicry models of autoimmune disease
Mogi et al. Increased β2-microglobulin in both parotid and submandibular/sublingual saliva from patients with Sjögren's syndrome
Infante et al. Evidence of a diverse T cell receptor repertoire for acetylcholine receptor, the autoantigen of myasthenia gravis
Holmes The chronic fatigue syndrome
RU2233290C2 (ru) Новые пептиды для применения в иммунотерапии аутоиммунных заболеваний
Juntunen et al. Suboptimal recognition of a T cell epitope of the major dog allergen Can f 1 by human T cells
Gerstner Anti-citrulline immunity in rheumatoid arthritis: characterization of peptide-HLA interactions and CD4+ T cell responses
WO2024023521A1 (en) Tolerogenic peptides
Arnold et al. Cell-mediated immunity in thyroid-associated ophthalmopathy
JPH11509538A (ja) Ｉｎ ｖｉｖｏ 糖尿病試験

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B90T Transfer of trial file for re-examination
E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080417

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee